TY - JOUR AU - Sari, Santi Purna AU - Putri, Icut Diki Adestia AU - Nursanti, Binar PY - 2018/12/20 Y2 - 2024/03/29 TI - COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE GENERIC AND PATENT IN CHILDREN WITH TYPHOID JF - International Journal of Applied Pharmaceutics JA - Int J App Pharm VL - 10 IS - 1 SE - Original Article(s) DO - 10.22159/ijap.2018.v10s1.16 UR - https://journals.innovareacademics.in/index.php/ijap/article/view/31426 SP - 76-80 AB - <p><strong>Objective</strong>: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effective<br />treatment.<br /><strong>Methods</strong>: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total sampling<br /><strong>method</strong>. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectiveness<br />of the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costs<br />of drugs, laboratory examinations, medical device usage, physician service, and hospitalization.<br /><strong>Results</strong>: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp<br />575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day.<br />Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.</p> ER -